<DOC>
	<DOC>NCT00549562</DOC>
	<brief_summary>This 8-week, prospective open-label study will investigate the effectiveness and tolerability of paliperidone ER in adolescents and young adults with autism. Hypothesis:Paliperidone Er will be well tolerated and efficacious for reducing aggression, self-injury, and irritability in adolescents and young adults.</brief_summary>
	<brief_title>Study of Paliperidone ER in Adolescents and Young Adults With Autism</brief_title>
	<detailed_description />
	<mesh_term>Autistic Disorder</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Males and females between ages of 12 and 21 years Tanner Sage III or IV (postpubertal) Diagnostic and Statistical Manual Fourth Edition TextRevised (DSMIVTR) diagnosis of autism Outpatient Ability to swallow pills Antipsychotic medicationfree for at least 2 weeks Score of 4 or more on the Clinical Global Impressions Severity Scale Score of 18 or higher on the Aberrant Behavior Checklist Irritability Scale Mental age of 18 months or greater based on testing Subjects must be in good physical health Asperger's Disorder, Pervasive Developmental Disorder Not Otherwise Specified (PDD NOS), Rett's Disorder, childhood disintegrative disorder, schizophrenia, bipolar disorder, Fragile X Syndrome, Tuberous Sclerosis A significant medical condition An active seizure disorder Females who are pregnant Evidence of a prior adequate trial of paliperidone ER History of neuroleptic malignant syndrome Hypersensitivity to paliperidone ER</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>Autistic Disorder</keyword>
</DOC>